Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study-Reference-Cited by-同舟云学术

Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study

Published:2005-10 Issue:5 Volume:15 Page:323-328
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Ichikawa Yoichi,Saito Terunobu,Yamanaka Hisashi,Akizuki Masashi,Kondo Hirobumi,Kobayashi Shigeto,Oshima Hisaji,Kawai Shinichi,Hama Nobuaki,Yamada Hidehiro,Mimori Tsuneyo,Amano Koichi,Tanaka Yasushi,Matsuoka Yasuo,Yamamoto Sumiki,Matsubara Tsukasa,Murata Norikazu,Asai Tomiaki,Suzuki Yasuo,

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/s10165-005-0420-z

Reference25 articles.

1. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

2. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial

3. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Treatment of Omega-3 Fatty Acids and Vitamin C Exhibited Promising Therapeutic Effect against Oxidative Impairment of the Liver in Methotrexate-Intoxicated Mice;BioMed Research International;2022-04-20

2. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review;Rheumatology;2021-04-28

3. Methotrexate and Oral Antirheumatic Drugs;Juntendo Medical Journal;2020

4. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA);Modern Rheumatology;2019-07-24

5. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis;International Journal of Rheumatic Diseases;2019-02-27